|
|
HP-?-CD |
|
Vaxjo ID |
496 |
|
Vaccine Adjuvant Name |
HP-?-CD |
|
Description |
carbohydrate vaccine adjuvant that induces Th1/Th2 balanced response |
|
Stage of Development |
Research |
|
Location Licensed |
Japan |
|
Host Species for Testing |
Mouse |
|
Second Host Species for Testing |
Monkey |
|
Structure |
cyclic oligosaccharide |
|
Function |
Type: carbohydrate vaccine adjuvant. Induces Th1/Th2 mixed immune profile. The adjuvant HP-?-CD temporarily releases IL-33 from alveolar epithelial type 2 cells in the lung, initiating an immune response through IL-33/ST2 signaling |
| References |
Kobari et al., 2020: Kobari S, Kusakabe T, Momota M, Shibahara T, Hayashi T, Ozasa K, Morita H, Matsumoto K, Saito H, Ito S, Kuroda E, Ishii KJ. IL-33 Is Essential for Adjuvant Effect of Hydroxypropyl-β-Cyclodexrin on the Protective Intranasal Influenza Vaccination. Frontiers in immunology. 2020; 11; 360. [PubMed: 32210964].
|
|
